Beam Therapeutics Statistics
Share Statistics
Beam Therapeutics has 82.81M shares outstanding. The number of shares has increased by 1.12% in one year.
| Shares Outstanding | 82.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 72.71M |
| Failed to Deliver (FTD) Shares | 3.43K |
| FTD / Avg. Volume | 0.32% |
Short Selling Information
The latest short interest is 12.31M, so 14.87% of the outstanding shares have been sold short.
| Short Interest | 12.31M |
| Short % of Shares Out | 14.87% |
| Short % of Float | 16.95% |
| Short Ratio (days to cover) | 13 |
Valuation Ratios
The PE ratio is -15.85 and the forward PE ratio is -5.86.
| PE Ratio | -15.85 |
| Forward PE | -5.86 |
| PS Ratio | 5.56 |
| Forward PS | 40.7 |
| PB Ratio | 2.14 |
| P/FCF Ratio | -11.48 |
| PEG Ratio | n/a |
Enterprise Valuation
Beam Therapeutics Inc. has an Enterprise Value (EV) of 1.84B.
| EV / Earnings | -13.86 |
| EV / Sales | 4.86 |
| EV / EBITDA | -11.74 |
| EV / EBIT | -10.41 |
| EV / FCF | -10.04 |
Financial Position
The company has a current ratio of 5.89, with a Debt / Equity ratio of 0.
| Current Ratio | 5.89 |
| Quick Ratio | 5.89 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.14% and return on capital (ROIC) is -15.45%.
| Return on Equity (ROE) | -0.14% |
| Return on Assets (ROA) | -0.09% |
| Return on Capital (ROIC) | -15.45% |
| Revenue Per Employee | 800.23K |
| Profits Per Employee | -280.78K |
| Employee Count | 472 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.37M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -1.79% in the last 52 weeks. The beta is 1.86, so Beam Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.86 |
| 52-Week Price Change | -1.79% |
| 50-Day Moving Average | 25.12 |
| 200-Day Moving Average | 26.29 |
| Relative Strength Index (RSI) | 55.43 |
| Average Volume (20 Days) | 1.06M |
Income Statement
In the last 12 months, Beam Therapeutics had revenue of $377.71M and earned -$132.53M in profits. Earnings per share was $-1.72.
| Revenue | 377.71M |
| Gross Profit | -59.67M |
| Operating Income | -176.49M |
| Net Income | -132.53M |
| EBITDA | -156.47M |
| EBIT | -176.49M |
| Earnings Per Share (EPS) | -1.72 |
Balance Sheet
The company has $435.89M in cash and $172.69M in debt, giving a net cash position of $263.21M.
| Cash & Cash Equivalents | 435.89M |
| Total Debt | 172.69M |
| Net Cash | 263.21M |
| Retained Earnings | -1.19B |
| Total Assets | 1.17B |
| Working Capital | 779.29M |
Cash Flow
In the last 12 months, operating cash flow was -$149.19M and capital expenditures -$33.73M, giving a free cash flow of -$182.93M.
| Operating Cash Flow | -149.19M |
| Capital Expenditures | -33.73M |
| Free Cash Flow | -182.93M |
| FCF Per Share | -2.37 |
Margins
Gross margin is -15.8%, with operating and profit margins of -46.73% and -35.09%.
| Gross Margin | -15.8% |
| Operating Margin | -46.73% |
| Pretax Margin | -34.73% |
| Profit Margin | -35.09% |
| EBITDA Margin | -41.43% |
| EBIT Margin | -46.73% |
| FCF Margin | -48.43% |
Dividends & Yields
BEAM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.16% |
| FCF Yield | -7.92% |
Analyst Forecast
The average price target for BEAM is $43.5, which is 55.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.5 |
| Price Target Difference | 55.9% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 2.43 |
| Piotroski F-Score | 4 |